Use of a liquid nicotine delivery product to promote smoking cessation

BMC Public Health

Research Article

Nicholas Geimer¹  Deborah Baumgarten²  Carl E Olson²  Martin C Mahoney³  James L Kepner⁴ 

[1] Department of Medical Oncology, Medical College of Wisconsin, 53226, Milwaukee, WI, USA;Department of Radiation Oncology, Columbia St. Mary's Hospital, 53211, Milwaukee, WI, USA;Departments of Health Behavior and Medicine, Roswell Park Cancer Institute, 14263, Buffalo, NY, USA;Statistics and Evaluation Center, American Cancer Society, 30329, Atlanta, GA, USA;

关键词: Nicotine;    Smoking Cessation;    Bupropion;    Nicotine Replacement Therapy;    Varenicline;   

DOI  :  10.1186/1471-2458-10-155

 received in 2009-09-09, accepted in 2010-03-24,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundDespite access to various pharmacotherapies and counseling support to aid cessation, smokers typically demonstrate quit rates below 50%. This report describes the results of a Phase 2a study exploring the efficacy of a liquid nicotine delivery system as an aid to smoking cessation assessed after 12 weeks of therapy.MethodsA single-arm Phase 2a study was conducted. Community-based smokers (ages 18+ years, smoking at least 10 cigarettes daily for the past year and interested in making a quit attempt) were recruited and completed clinic visits at 2 week intervals over the 12 week study period where carbon monoxide levels were assessed and the Smoke-Break product was rated on taste and overall satisfaction. Participants were provided with a supply of liquid nicotine cigarettes (e.g., Smoke-Break) at each clinic visit. A total of 69 smokers were enrolled and received the intervention product (intention to treat group, ITT) and 52 smokers verified participation (according to protocol group, ATP).ResultsThe cessation rate at 12 weeks after the baseline visit, assessed as the bioverified point prevalence of abstinence, was 71.1% (95% confidence interval [CI] 58.8%-83.5%) in the ATP group and 53.6% (41.8%-65.4%) in the ITT group. Participants rated the liquid nicotine delivery system highly and also expressed general satisfaction. Few adverse events were identified with no serious adverse events.ConclusionsThese results support the efficacy of the liquid nicotine delivery system in smoking cessation. If this nicotine delivery product proves to be effective in larger trials, it could represent an inexpensive, readily accessible and well-tolerated agent to promote smoking cessation.Trial RegistrationThis trial is registered at clinicaltrials.gov as study NCT00715871.

【 授权许可】

Unknown   
© Geimer et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.